MaxCyte, Inc. Grant of Options and PDMR Dealing (7652T)
March 22 2023 - 3:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7652T
MaxCyte, Inc.
22 March 2023
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options and PDMR Dealing
Gaithersburg, Maryland - 22 March 2023: MaxCyte Inc., (NASDAQ:
MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery,
development, and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research ,
announces that on 20 March 2023, a total of 480,000 options of
common stock in the Company ("Common Stock") were granted to PDMRs
of the Company ("Option Grants"). Details of the Option Grants are
given below:
Option Grants to
PDMRs
Doug Doerfler 400,000
--------
Rekha Hemrajani 40,000
--------
Yasir Al-Wakeel 40,000
--------
Total 480,000
--------
Options granted to Doug Doerfler vest 12/48(th) of the total
grant one year after date of grant, and thereafter vest 1/48 (th)
per month for 36 months after the date of grant.
Of the option granted to Rekha Hemrajani and Yasir Al-Wakeel,
Non-Executive Directors of the Company, 23,333 of the Option Grants
vested on the date of the grant, and the remaining 16,667 shares
will vest in 15 equal monthly installments thereafter, beginning on
April 14, 2023.
The Option Grants have an exercise period of 10 years from date
of grant, at which time they will expire, and have an exercise
price equal to the closing price of MaxCyte's stock on 20 March
2023, being $4.19.
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation(R) technology, which facilitates
complex engineering of a wide variety of cells. Our ExPERT(TM)
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx(R),
STx(R) GTx(R) and VLx(TM); a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio.
Learn more at maxcyte.com and follow us on Twitter and LinkedIn
.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name a) Doug Doerfler
b) Rekha Hemrajani
c) Yasir Al-Wakeel
--------------------------------- ---------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------
a) Position/status a) President and CEO
b) Non-Executive Director
c) Non-Executive Director
--------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name MaxCyte Inc.
--------------------------------- ---------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the Common Stock of $0.01 each
financial instrument,
type of instrument
Identification code US57777K1060
b) Nature of the transaction Grant of options of common stock
--------------------------------- ---------------------------------------
c) Price(s) and volume(s)
---------------------- ------------
Exercise Price(s) Volume(s)
---------------------- ------------
a) $4.19 400,000
------------------------------------------------------------- ------------
b) $4.19 40,000
------------------------------------------------------------- ------------
c) $4.19 40,000
------------------------------------------------------------- ------------
d) Aggregated information
- Aggregated volume 480,000
- Price $4.19
e) Date of the transaction March 20, 2023
--------------------------------- ---------------------------------------
f) Place of the transaction USStock Exchange, Nasdaq
--------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBRGDXXGDDGXB
(END) Dow Jones Newswires
March 22, 2023 03:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
